Johnson & Johnson (NYSE:JNJ) is one of the 10 Unrivaled Stocks of the Next 3 Years. On September 3, Wolfe Research increased the price target for Johnson & Johnson (NYSE:JNJ) from $175 to $195 and kept an Outperform rating. Wolfe Research cited growing confidence in Johnson & Johnson’s (NYSE:JNJ) upcoming talc litigation outcome. This confidence led the firm to use lower weighted average cost of capital (WACC) assumptions in its discounted cash flow analysis. Wolfe Research Lifts PT for Johnson & Johnson ...

Core Thesis - Deckers Outdoor Corporation is positioned as a strong player in the footwear industry, driven by the success of its brands UGG and Hoka, with a bullish outlook on its growth potential [1][2]. Financial Performance - As of September 3rd, Deckers' share price was $123.67, with trailing and forward P/E ratios of 18.88 and 19.88 respectively [1]. - Hoka experienced a sales growth of 29.3% in the first three quarters of 2025, contributing nearly 42% to total revenue [2]. - UGG, the largest brand, accounted for just over 54% of revenue and grew by 14.9% during the same period [3]. - The company's gross profit margin improved from 50.3% in 2023 to 60.3% by Q3 2025, reflecting a 1000 basis point increase [3]. - Deckers has no long-term debt and boasts a return on invested capital of 32.7%, with net income margins at 25% [4]. Strategic Initiatives - The shift towards direct-to-consumer (DTC) sales has been significant, with DTC now representing over 55% of net sales, up from 43% through wholesale channels [3]. - This DTC model has enhanced digital customer acquisition and expanded profit margins [3]. Valuation and Market Position - A discounted cash flow analysis indicates an intrinsic value of $124 per share, suggesting that the market may be undervaluing the company's growth potential [5]. - Despite strong fundamentals, Deckers' stock has declined nearly 45% year-to-date, indicating a disconnect between its financial performance and market valuation [4]. Market Sentiment - Previous analyses have highlighted Deckers' strong fundamentals and brand equity, with a recent appreciation of approximately 2% in stock price since earlier coverage [6].

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, aimed at both novice and experienced investors [1] - The newsletter provides insights on key trends, catalysts driving valuations, product sales forecasts, and integrated financial statements for major pharmaceutical companies [1] - The author, Edmund Ingham, has over 5 years of experience in covering biotech, healthcare, and pharma, and has prepared detailed reports on more than 1,000 companies [1]